BioSpace News Archive

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated first-quarter 2024 financial results and provided Company updates.

Centogene N.V. today announced the discovery of a new small molecule together with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO).

Children’s Hospital of Philadelphia announced it has entered into a Memorandum of Understanding with Sidra Medicine, a specialty healthcare organization for women, children and young people in Qatar.

Neurocrine Biosciences, Inc. presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH).

Dynavax Technologies Corporation provided a regulatory update for the Company’s supplemental Biologics License Application to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine, Adjuvanted] regimen for adults on hemodialysis.

Genprex, Inc. today announced that the first patient has been enrolled and dosed in the Company’s Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech’s Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, announced that it has entered into a distribution agreement with CB Medical, LLC for the sale and distribution of the Company’s UroShield.

Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024.

GRI Bio, Inc., a biotechnology company advancing an innovative pipeline of Natural Killer T cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 2:40 PM ET.

OrthAlign, Inc., a leading innovator in surgical technology, announces the launch of its flagship product, Lantern, in Japan.